Argenta Discovery Ltd has extended its existing lead optimization project with H. Lundbeck A/S, in which Argenta is optimizing lead compounds within one of Lundbeck's Central Nervous System (CNS) programs. This collaboration has also been expanded to include a new agreement on an additional Lundbeck target.
Under the terms of the new agreement, Argenta will generate focussed hit-finding libraries to identify druggable inhibitors of a Lundbeck nominated target. Argenta will generate the libraries using a combination of medicinal and synthetic chemistry expertise, SAR analysis and in silico profiling.
Commenting on the agreement, Dr Anthony Baxter, Argenta's CEO, said: "We are delighted to announce that our initial collaboration with Lundbeck has been extended, and that we will be working with Lundbeck on a new target. In outsourcing, where one of the key indications of a successful project is repeat business, customer satisfaction is paramount. The consolidation of this relationship provides evidence of the expertise and experience of our scientific staff."